Prostate Cancer News on BioPortfolio

Apalutamide in nmCRPC QOL as Good as ADT Alone

SPARTAN shows that healthrelated quality of life QOL is not compromised by adding apalutamide to background ADT in men with nonmetastatic castrateresistant prostate cancer nmCRPC. Medscape Medical News

Drug Master File for Prostate Imaging Product Filed with the FDA

MELBOURNE Australia and INDIANAPOLIS March 26 2018 GLOBE NEWSWIRE Telix Pharmaceuticals Limited ASX.TLX "Telix Group" "Company" a clinicalstage biopharmaceutical company focused on the development of diagnostic and th...

Pages